Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000902664-26-001544·Celldex Therapeutics, Inc.
Schedule 13G ownership disclosure
Celldex Therapeutics Inc
Common Stock, par value $0.001 per share · CUSIP: 15117B202
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Point72 Asset Management, L.P.
Shares: 1,758,357.00 · Class: 2.6%
- Point72 Capital Advisors, Inc.
Shares: 1,758,357.00 · Class: 2.6%
- Steven A. Cohen
Shares: 1,758,357.00 · Class: 2.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-26-001544
- Form type
- SCHEDULE 13G/A
- Filer
- Celldex Therapeutics, Inc.
- CIK
- CIK 744218
- Filed
- Mar 10, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership